Evidence map›Paper›PMID 36901787›Full record

ReviewInternational journal of molecular sciences2023

Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance.

Amaia Ezkurdia, María J Ramírez, Maite Solas

Registry-linked trialFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06632470 (Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment), which is not on this map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06632470 phase1not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)

TypeinterventionalSponsorBaermedRan2024 to 2025Enrolled54ConditionsDementia, Moderate DementiaArmsSecretome injection, Vitamin B12 Injection
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amaia EzkurdiaDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-8557-4331
María J RamírezDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-3488-9579
Maite SolasDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-7670-3237

Funding

Ministerio de ciencia e innovación, Spain PID2021-128737NB-I00
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the main type of dementia and is a disease with a profound socioeconomic burden due to the lack of effective treatment. In addition to genetics and environmental factors, AD is highly associated with metabolic syndrome, defined as the combination of hypertension, hyperlipidemia, obesity and type 2 diabetes mellitus (T2DM). Among these risk factors, the connection between AD and T2DM has been deeply studied. It has been suggested that the mechanism linking both conditions is insulin resistance. Insulin is an important hormone that regulates not only peripheral energy homeostasis but also brain functions, such as cognition. Insulin desensitization, therefore, could impact normal brain function increasing the risk of developing neurodegenerative disorders in later life. Paradoxically, it has been demonstrated that decreased neuronal insulin signalling can also have a protective role in aging and protein-aggregation-associated diseases, as is the case in AD. This controversy is fed by studies focused on neuronal insulin signalling. However, the role of insulin action on other brain cell types, such as astrocytes, is still unexplored. Therefore, it is worthwhile exploring the involvement of the astrocytic insulin receptor in cognition, as well as in the onset and/or development of AD.

Indexed as

Alzheimer DiseaseDiabetes Mellitus, Type 2Insulin ResistanceMetabolic SyndromeBrainHumansInsulinInsulin, Regular, HumanRisk FactorsInsulinInsulin, Regular, Humanastrocytediabetes mellitushyperlipidemiahypertensioninsulin resistanceobesity

Identifiers

PMID36901787
PMCPMC10001958

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read5
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.